Asfotase alfa is indicated for:
Population group: both men and women, only children (1 year - 12 years old) , adolescents (12 years - 18 years old) , adults (18 - 65 years old)
Asfotase alfa is indicated for long-term enzyme replacement therapy in patients with paediatric-onset hypophosphatasia to treat the bone manifestations of the disease.
For this indication, competent medicine agencies globally authorize below treatments (click for details):